XML 53 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible Assets (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
IPR and D Drug Technology Platforms [Member]            
Restructuring Cost and Reserve [Line Items]            
Asset impairment charges $ 0   $ 0 $ 0 $ 0  
IPR and D Drug Technology Platforms [Member] | Ovarian Cancer [Member]            
Restructuring Cost and Reserve [Line Items]            
Finite-lived intangible assets acquired       13,400,000    
EGEN Inc [Member]            
Restructuring Cost and Reserve [Line Items]            
Goodwill $ 2,000,000.0     2,000,000.0    
EGEN Inc [Member] | Purchase Agreement [Member]            
Restructuring Cost and Reserve [Line Items]            
Finite-lived intangible assets acquired       $ 1,600,000    
Finite-lived intangible asset, useful life       7 years    
Amortization       $ 56,829    
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member]            
Restructuring Cost and Reserve [Line Items]            
Asset impairment charges           $ 2,000,000.0
Non-cash charge   $ 2,000,000.0        
EGEN Inc [Member] | IPR and D Drug Technology Platforms [Member]            
Restructuring Cost and Reserve [Line Items]            
Estimated acquisition price       24,200,000    
Impairment asset       10,800,000    
Indefinite-lived intangible assets acquired       $ 13,400,000